MENLO PARK, Calif. & TORONTO--(BUSINESS WIRE)--Dec. 13, 2005--Depomed, Inc. (NASDAQ:DEPO) of Menlo Park, California, and Biovail Corporation (NYSE:BVF)(TSX:BVF) of Canada today announced that the companies have reached a definitive agreement to revise the terms of their partnership agreement for the development and commercialization of Glumetza(tm), a once-daily, extended-release formulation of metformin hydrochloride (HCl) for the treatment of Type II diabetes.
